What is the market's earnings forecast for Repligen next quarter?

What is Repligen's gross profit margin?

What is the revenue and EPS growth rate for Repligen year over year?

What is Repligen's latest dividend and current dividend yield?

What factors drove the changes in Repligen's revenue and profit?

Did Repligen beat or miss consensus estimates last quarter?

What does Repligen do and what are its main business segments?

What guidance did Repligen's management provide for the next earnings period?

- **Revenue Growth**: 14% organic in 2025, with 2026 guidance of 10-14% driven by Analytics upgrades and China recovery.
- **Margin Expansion**: 150bps target in 2026, supported by volume leverage and pricing, offset by minor tariff headwinds.
- **Strategic Wins**: SoloVPE PLUS upgrades, China market expansion, and service cross-selling initiatives.
- **Risks**: Tariff uncertainty, MFN-related CapEx delays, and FX volatility.


**【CEO Summary Section】**
- Repligen achieved 14% organic revenue growth in 2025, driven by strong performance across all franchises: Proteins (+31%), Chromatography (+25%), and Filtration (+8%).
- CEO Olivier Loeillot emphasized strategic priorities: outpacing bioprocessing industry growth, margin expansion, and innovation. 2026 guidance includes 9-13% organic growth, with key opportunities in Analytics (SoloVPE PLUS upgrades) and China market recovery.
- New product launches (e.g., ProConnex MixOne mixer) and partnerships (e.g., Novasign) support long-term growth.

**【CFO Financial Commentary】
- 2025 adjusted EBITDA margin expanded to 19%, with $1.71 EPS, exceeding expectations. 2026 guidance projects $810-840M revenue (10-14% growth) and 150bps margin expansion.
- Tariffs and FX assumptions moderate growth, but volume leverage and pricing drive margin improvement.
- OpEx investments focus on IT modernization, Asia expansion, and leadership development.

**【Q&A Highlights】**
- **Tariffs & Macro Environment**: CFO Jason Garland noted tariffs as a minor headwind (50bps), with focus on FX stability and onshoring opportunities.
- **China Recovery**: Sequential growth in Q4 2025 orders suggests 2026 recovery, supported by new office openings and partnerships.
- **Service Growth**: Services (6% of 2025 revenue) target 10%+ by 2027, with incentives for cross-selling and service contracts.
- **Capital Equipment**: Low double-digit growth expected, driven by Analytics and PATsmart portfolio integration.
- **MFN Impact**: Large pharma delays CapEx, but 2026 guidance assumes normalization post-MFN digestion.


Repligen Corporation (RGEN) Q4 2025 Earnings Call Transcript

- **Record Q3 Growth**: 18% organic revenue driven by Analytics (+50%), Filtration (+20%), and Asia Pacific (+50%).
- **Strategic Initiatives**: Digitization partnerships (Novasign), 20 strategic accounts, and $729-737M updated guidance.
- **Margin Expansion**: Gross margin 53.3% (+260bps YoY), operating margin 14.2%.
- **China Recovery**: Expected 2026 growth after Q3 2025 softness.
- **Equipment Momentum**: 20%+ capital equipment growth, with ATF upgrades and analytics upgrades driving orders.

**【CEO Summary Section】**
- **Q3 2025 Organic Growth**: 18% year-over-year, driven by double-digit growth across all franchises (Analytics +50%, Filtration +20%, Chromatography +25%).
- **Asia Pacific Dominance**: 50% revenue growth, with strong contributions from Fluid Management, Analytics, and ATF.
- **Digitization Strategy**: Integration of CTech VPX with TFF systems for real-time monitoring; partnership with Novasign for digital twin capabilities.
- **Strategic Accounts**: 20 large pharma/CDMO accounts now buying multiple products, contributing to cross-selling success.
- **Emerging Biotech Recovery**: Revenue at highest level in 3 years, linked to improved funding trends.

**【CFO Financial Commentary】**
- **Q3 2025 Results**: Revenue $189M (+22% YoY), Adjusted Gross Profit $101M (+28% YoY), Adjusted EPS $0.46.
- **Updated Guidance**: Organic growth narrowed to 14-15.5% (midpoint +75bps), with $729-737M revenue range.
- **Margin Expansion**: Gross margin 53.3% (+260bps YoY), operating margin 14.2%.
- **China Outlook**: Expected return to growth in 2026, despite Q3 2025 softness.
- **Tariffs & FX**: $1M FX headwind in Q3, minimal tariff impact in 2025.

**【Q&A Highlights】**
- **Order Momentum**: 6th consecutive quarter of >20% YoY order growth, with no single driver.
- **Gene Therapy Headwind**: $3M+ impact in H2 2025 from a large filtration customer.
- **Equipment Growth**: 20%+ capital equipment revenue, driven by ATF and analytics upgrades.
- **2026 Outlook**: CEO expects to outpace industry growth by 5%, with focus on Asia Pac and new modalities.
- **Service Expansion**: Services now 5% of revenue, targeting broader capital equipment attach rates.

Repligen Corporation (RGEN) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: 17% organic non-COVID growth in Q2, driven by biopharma (20%), CDMOs, and capital equipment (high teens). Orders up 20% YoY.
- **China Recovery**: 40% YoY order growth in Q2, with cautious optimism for 2026 recovery.
- **Gene Therapy Headwind**: $13M H1 revenue but minimal H2 contribution, offset by cell therapy and ADC growth.
- **Margin Expansion**: 2025 gross margin 52%-53%, EPS $1.65-$1.72, with 160-260bps expansion from volume and productivity.
- **Long-Term Vision**: Doubling revenue in 5 years via 5%+ market outperformance, strategic investments, and modest M&A.

**【CEO Summary Section】**
- **Q2 2025 Highlights**: 17% organic non-COVID revenue growth, driven by mid-teens growth across all regions. Orders grew 20% YoY, with filtration leading at over 40% growth.
- **Strategic Investments**: Increased manufacturing labor to meet demand, with dual U.S.-Europe manufacturing to mitigate tariffs. Gross margin expected to improve in H2.
- **Market Momentum**: Biopharma and CDMO revenues up 20%, capital equipment revenue in high teens. China orders rebounded 40% YoY, signaling potential recovery.
- **New Modalities**: Gene therapy platform contributed $13M in H1 but expected to flatten in H2, with headwind of 1% to 2025 guidance. Cell therapy and ADCs show growth potential.

**【CFO Financial Commentary】**
- **Q2 Financials**: Revenue $182M (+15% YoY), gross margin 51.1%, adjusted EPS $0.37. Strong cash position ($709M) and free cash flow generation.
- **Guidance Update**: 2025 revenue raised to $715M-$735M (12.5%-15.5% organic growth). Gross margin 52%-53%, EPS $1.65-$1.72. Tariffs and FX neutral impact.
- **Margin Expansion**: 160-260bps gross margin expansion driven by volume, pricing, and productivity. Operating expenses growing slower than revenue.

**【Q&A Key Highlights】**
- **China Recovery**: New leadership and tariff dynamics drove 40% YoY order growth. Expect gradual recovery in 2026 with strategic investments.
- **Capital Equipment Strength**: ATF and downstream systems sales up high teens, 25% of systems include PAT tech. Equipment/orders ratio >1 for 8 quarters.
- **Gene Therapy Headwinds**: $10M H1 gene therapy revenue, $3M in July, but minimal H2 contribution. Diversified new modalities (cell therapy, ADCs) offsetting.
- **Tariff Strategy**: Passing surcharges to customers, modest price actions. Dual manufacturing to reduce risk by 2024.
- **Long-Term Growth**: Doubling revenue in 5 years via organic growth (5%+ above market) and modest M&A. 2025-2026 focus on execution and margin expansion.

Repligen Corporation (RGEN) Q2 2025 Earnings Call Transcript

- **Strong Q1 Growth**: 14% organic non-COVID revenue growth, driven by proteins (record sales), chromatography (50%+ order growth), and analytics (20% expansion).
- **Tariff Resilience**: Minimal EPS impact from tariffs; 90% U.S. revenue manufactured domestically, with surcharges to offset costs.
- **Strategic Wins**: 908 Devices acquisition adds $10M+ annual revenue; new Metenova mixer orders expected in H2 2025.
- **Profitability Expansion**: Gross margin up 450bps YoY to 53.7%; operating income up 72% YoY.
- **2025 Outlook**: Organic non-COVID growth 11.5%-15.5%, with EBITDA margin 19.3% and EPS $1.63-$1.72.

**【CEO Summary Section】**
- **Q1 2025 Revenue Growth**: Organic non-COVID revenue increased 14% year-over-year to $169 million, driven by double-digit growth across all product lines (chromatography, proteins, filtration, and analytics). Orders rose 18% year-over-year, with sequential growth from Q4 2024.
- **Key Business Highlights**: 
  - Proteins segment saw record sales, fueled by strong demand for chromatography resins.
  - Chromatography orders jumped over 50%, with new wins in large pharma customers.
  - Analytics revenue grew 20%, including $1 million from the 908 Devices acquisition.
- **Strategic Initiatives**: 
  - Acquired 908 Devices' bioprocessing portfolio to expand PAT capabilities.
  - Launched new Metenova single-use mixer, with initial orders expected in H2 2025.
  - Invested in global manufacturing optimization to mitigate tariff risks.
- **Tariff Impact**: Estimated 10% of COGS and low single-digit revenue exposure, but surcharges and pricing actions could offset costs, resulting in minimal EPS impact.

**【CFO Financial Commentary】**
- **Gross Margin**: 53.7% (up 450bps YoY), driven by volume leverage and favorable mix (proteins). Q1 margin may be the highest for the year.
- **Operating Income**: $23 million (up 72% YoY), with OpEx growth of 6% organically vs. 14% revenue growth.
- **EPS**: $0.39 (up 29% YoY), with tax rate stable at 23.1%.
- **Full Year Guidance**: 
  - Organic non-COVID revenue growth: 11.5%-15.5%
  - Adjusted EBITDA margin: 19.3%
  - EPS: $1.63-$1.72 (down $0.04 from prior range)
  - Includes $10 million+ impact from 908 acquisition

**【Q&A Key Themes】**
- **Tariff Mitigation**: 90% of U.S. revenue manufactured domestically; surcharges and pricing actions to offset costs.
- **New Modalities**: Orders up >20% YoY, with 9 of top 10 CDMOs using ATF technology.
- **China Risk**: Represents <2% of revenue, with no material impact on 2025 outlook.
- **CDMO Growth**: Orders up 40% YoY, driven by OPUS column adoption and ATF consumables.
- **Gross Margin Cadence**: Q1 peak of 53.7%, with sequential decline due to protein mix but offset by productivity gains.

Repligen (RGEN)-29 Apr 25-2025 Q1 Earnings call transcript

- **Revenue Surge**: Q4 2024 revenue up 13% YoY (non-COVID), with orders at 3-year high. 
- **CDMO Revival**: CDMO sales +40% YoY, equipment orders +30% sequential. 
- **New Modalities Growth**: 25 accounts exceed $1M, 20% of revenue from new modalities. 
- **Profitability Boost**: Gross margin 50.7%, EBITDA 20.9%, cash flow $42M. 
- **2025 Guidance**: $685M-$710M (8-12% growth), 100-200bps margin expansion. 
- **China Turning**: Orders up 6% H2/H1, 2025 flat to growth. 
- **EPS Outlook**: $1.67-$1.76 for 2025, up 0.09-0.18.

**【CEO Summary Section】**
- **Revenue Growth**: Q4 2024 revenue reached $167.5 million, up 13% YoY (non-COVID basis), with full-year revenue of $634.4 million. Orders hit the highest level since Q2 2022, driven by strong performance in CDMOs and equipment. 
- **CDMO Recovery**: CDMO sales grew 40% YoY in Q4, with orders up 11% YoY, signaling a durable market recovery. Equipment sales and orders rose over 30% sequentially. 
- **New Modalities**: 20% of revenue now comes from new modalities, with 25 accounts exceeding $1 million in sales. Launches like CrossFlow RS10 and AviPure resin are driving differentiation. 
- **2025 Outlook**: Guidance of $685M-$710M (8%-12% growth), with focus on accelerating growth in Asia, R&D investment, and margin expansion (100-200bps). 

**【CFO Financial Commentary】**
- **Profitability**: Q4 adjusted gross margin 50.7%, up 140bps YoY. Full-year adjusted EBITDA margin 20.9%, with $42M cash flow from operations. 
- **Cost Control**: Operating expenses grew 4% YoY, driven by performance-based bonuses. Restructuring charges ($45M) were non-recurring. 
- **EPS Performance**: Q4 adjusted EPS $0.44, full-year $1.58. 2025 EPS guidance $1.67-$1.76, up 0.09-0.18. 
- **Liquidity**: $757M cash balance, supporting M&A and growth investments. 

**【Q&A Highlights】**
- **CDMO Momentum**: Tier 1 and 2 CDMOs showed 20%+ sequential growth, with 9/10 top CDMOs using ATF. 
- **ATF Expansion**: ATF consumables now >50% of filtration revenue, with design wins in 3+ blockbuster drugs. 
- **China Recovery**: Orders up 6% H2/H1, with 2025 flat to growth outlook. 
- **Margins & Pricing**: 2025 gross margin 51-52%, with low single-digit price realization. 
- **M&A Pipeline**: 1-2 deals planned for new modalities and PAT, with $757M cash for flexibility.

Actual											0.32	0.42	0.4	0.52	0.68	0.79	0.78	0.81	0.92	0.91	0.77	0.68	0.64	0.53	0.23	0.33	0.28	0.33	0.43	0.44	0.39	0.37	0.46	0.49
Forecast											0.2213	0.2777	0.2762	0.3063	0.4225	0.5238	0.6369	0.6488	0.72	0.7138	0.6799	0.5766	0.5883	0.4751	0.1649	0.3258	0.301	0.3261	0.3354	0.4103	0.3461	0.3882	0.4216	0.4412
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+44.60%	+51.24%	+44.82%	+69.77%	+60.95%	+50.82%	+22.47%	+24.85%	+27.78%	+27.49%	+13.25%	+17.93%	+8.79%	+11.56%	+39.48%	+1.29%	-6.98%	+1.20%	+28.21%	+7.24%	+12.68%	-4.69%	+9.11%	+11.06%

RGEN

RGEN fundamentals

RGEN Q4 2025 Earnings

Earnings Call

You can ask Aime

RGEN

RGEN fundamentals

RGEN Q4 2025 Earnings

Earnings Call

RGEN Earnings Call Summary for Q4/20258:30 AM on Feb 24, 2026

RGEN Earnings Call Summary for Q3/20258:30 AM on Oct 28, 2025

RGEN Earnings Call Summary for Q2/20258:30 AM on Jul 29, 2025

RGEN Earnings Call Summary for Q1/20258:30 AM on Apr 29, 2025

RGEN Earnings Call Summary for Q4/20248:30 AM on Feb 20, 2025

You can ask Aime